Michael Megaly, MD
Cardiovascular Disease · Detroit, MINPI 1083029755
Payments from drug & device makers
Across 243 payments — averaging $392.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$51K
- Boston Scientific$26K
- Medtronic$4K
- Penumbra, Inc.$4K
- Abiomed$3K
- Asahi Intecc USA, Inc.$1K
- plus $6K from 32 others
What the payments were for
- Consulting fees$2901%
- Grants$25,14056%
- Travel & lodging$6,58615%
- Food & beverage$12,56128%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 25 | $50,565 |
| Boston Scientific | 19 | $26,224 |
| Medtronic(2 entities) | 39 | $4,446 |
| Penumbra, Inc. | 13 | $3,904 |
| Abiomed | 36 | $3,231 |
| Asahi Intecc USA, Inc. | 5 | $1,394 |
| Abbott | 11 | $1,028 |
| Inari Medical, Inc. | 20 | $731 |
| Shockwave Medical, Inc | 5 | $438 |
| Teleflex LLC | 6 | $389 |
| W. L. Gore & Associates, Inc. | 2 | $328 |
| Agepha Pharma FZ LLC | 1 | $311 |
| Acist Medical Systems, Inc. | 1 | $267 |
| Pfizer | 13 | $230 |
| Cardiovascular Systems Inc. | 2 | $196 |
| Livanova USA, Inc. | 2 | $194 |
| AstraZeneca | 3 | $152 |
| Chiesi USA, Inc. | 1 | $125 |
| Inquis Medical, Inc. | 1 | $115 |
| Bard Peripheral Vascular, Inc. | 1 | $99 |
| Irhythm Technologies, Inc. | 5 | $97 |
| Cardinal Health 200 LLC | 2 | $92 |
| Stryker | 3 | $91 |
| Terumo Medical Corporation | 1 | $88 |
| Merck | 5 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $76 |
| Itamar Medical Inc | 2 | $56 |
| Edwards Lifesciences | 1 | $55 |
| Boehringer Ingelheim | 3 | $45 |
| Bayer | 2 | $42 |
| Philips North America LLC | 1 | $38 |
| Biotronik Inc. | 1 | $33 |
| Amgen | 1 | $25 |
| Verge Medical, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| ZOLL Circulation Inc | 1 | $18 |
| Reflow Medical Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STENTS$25,000
- Indigo System$3,554
- Impella$1,939
- Resolute$1,190
- TurboHawk$1,030
- Asahi Peripheral Vascular Wires$654
- Asahi Coronary Wires$463
- VenaSeal$448
- LODOCO$311
- FLOWTRIEVER CATHETER, S$299
- CT THROMBECTOMY SYSTEM KIT$299
- Product in Development$290
- Dragonfly OCT$273
- CVI SYSTEMS$267
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$195
- LifeSPARC System$156
- GENERAL VASCULAR ACCESS$150
- COREVALVE EVOLUT R$147
- Optis Coronary Imaging System$147
- TURNPIKE$144
How this compares
$95,281 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $46,885 |
| BrilintaTicagrelor | 19 | $11,796 |
| JardianceEmpagliflozin | 16 | $10,428 |
| EntrestoSacubitril/Valsartan | 18 | $10,238 |
| Repatha SureclickEvolocumab | 11 | $9,365 |
| Ezetimibe | 218 | $8,780 |
| Rosuvastatin Calcium | 204 | $5,313 |
| Prasugrel Hcl | 27 | $2,916 |
| ClopidogrelClopidogrel Bisulfate | 62 | $1,672 |
| Metoprolol Succinate | 97 | $1,388 |
| Carvedilol | 134 | $1,367 |
| Bumetanide | 44 | $1,306 |
| Atorvastatin Calcium | 63 | $1,301 |
| Diltiazem 12hr ErDiltiazem Hcl | 11 | $1,255 |
| Nifedipine ErNifedipine | 44 | $945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $230 | $46,88553 claims |
| AstraZenecaBrilinta | $152 | $11,79619 claims |
| Boehringer IngelheimJardiance | $45 | $10,42816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Detroit
- Brian OneillDetroit$1.4M
- Pedro Villablanca SpinettoDetroit$844K
- Khaled Abdul NourDetroit$735K
- David LanfearDetroit$719K
- Gerald KoenigDetroit$612K
- Mouaz Al-MallahDetroit$475K
- Sachin ParikhDetroit$458K
- Karthikeyan AnanthasubramaniamDetroit$355K
- Pedro Engel GonzalezDetroit$345K
- Wayne WeaverDetroit$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.